Get to know our clinical trials

Clinical trial to evaluate Enoblituzumab in combination with Retifanlimab or Tebotelimab in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck

THE CLINICAL TRIAL AIMS TO ANSWER THE FOLLOWING QUESTIONS: WHAT ARE THE SIDE EFFECTS OF THESE EXPERIMENTAL DRUGS? HOW LONG DO THE EXPERIMENTAL DRUGS REMAIN IN THE BLOOD? ARE THESE EXPERIMENTAL DRUGS ACTIVE AGAINST YOUR TUMOR?

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 2, OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC EPIDERMOID CARCINOMA OF THE HEAD AND NECK. IMMUNOTHERAPY.
  • Protocol number: CP-MGA271-06
  • Promoter: MacroGenics, Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.